Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 271-085-1
CAS number: 68515-43-5
Statistically significant increases in aberrant cells compared with the
relevant control values were seen in cultures treated with the positive
controls Mitomycin-C and Cyclophosphamide, indicating the correct
functioning of the assay system.
Following treatment with the test item, no statistically significant
increase in the incidence of cells bearing aberrations including or
excluding gaps over the control values, was observed in any experiment
both in the absence or presence of S9 metabolism.
to cause chromosomal damage in cultured human lymphocytes, following in
vitro treatment in the absence and presence of S9 metabolic
activation has been investigated according to OECD/EU test methods.
statistically significant increase in the incidence of cells bearing
aberrations, including or excluding gaps, was observed at any dose level
or any sampling time.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again